A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial☆-Reference-Cited by-同舟云学术

A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial☆

Published:2021-03 Issue:3 Volume:32 Page:368-374
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Park S.H.,Lim D.H.,Sohn T.S.,Lee J.,Zang D.Y.,Kim S.T.,Kang J.H.,Oh S.Y.,Hwang I.G.,Ji J.H.,Shin D.B.,Yu J.I.,Kim K.-M.,An J.Y.,Choi M.G.,Lee J.H.,Kim S.,Hong J.Y.,Park J.O.,Park Y.S.,Lim H.Y.,Bae J.M.,Kang W.K.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference16 articles.

1. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction;Macdonald;N Engl J Med,2001

2. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach;Kim;Int J Radiat Oncol Biol Phys,2005

3. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial;Bang;Lancet,2012

4. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine;Sakuramoto;N Engl J Med,2007

5. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial;Lee;J Clin Oncol,2012

Cited by 149 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Retrospective Analysis of the Lauren Classification in the Choice of XELOX or SOX as an Adjuvant Chemotherapy for Gastric Cancer;Current Gene Therapy;2024-04

2. Choosing the right adjuvant therapy for stage III–IVA endometrial cancer: A comparative analysis of chemoradiotherapy and chemotherapy;Gynecologic Oncology;2024-03

3. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer;ESMO Open;2024-02

4. Risk factors for early recurrence after radical gastrectomy followed by adjuvant chemotherapy for stage II or III gastric cancer: a multicenter, retrospective study;Japanese Journal of Clinical Oncology;2024-01-20

5. Gastric Cancer Survivorship: Multidisciplinary Management, Best Practices and Opportunities;Journal of Gastrointestinal Cancer;2024-01-05